Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAVATAK and Ipilimumab in Advanced Melanoma
NCT02307149Phase 1Completed
- Sponsor
- Viralytics Ltd
- Start
- May 2015
- Primary completion
- Nov 2019
- Modality
- Oncolytic Viruses, Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of coxsackievirus a21 in melanoma, sponsored by Viralytics Ltd. Primary endpoint: Overall Response Rate at 106 days. Started May 2015; status: completed.
02
Drugs
coxsackievirus a21
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02307149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02307149.